The European majors are set to dominate 2023 in terms of high-profile clinical trials readouts and it will be a year where studies of new indications of marketed drugs become more important than ever before.
Looking particularly strong on the clinical catalyst front are AstraZeneca PLC, Novo Nordisk A/S and Novartis AG,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?